Trametinib Plus Dabrafenib in Patients With Unresectable or Distant Metastatic BRAF V600–Mutant Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
Eur. J. Cancer 2022 Sep 25;175(2022)254-262, C Dutriaux, C Robert, JJ Grob, L Mortier, O Dereure, C Lebbe, S Mansard, F Grange, EM Neidhardt, T Lesimple, L Machet, C Bedane, H Maillard, S Dalac-Rat, C Nardin, A Szenik, A Denden, P SaiagFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.